AlignRx

Avatar
drug cost graphic

How employers and TPAs can ease the rising cost of specialty drugs with medical rebates

The pharmaceutical industry is in the middle of a dynamic shift that shows no signs of slowing down. Traditional drug pipelines are now increasingly dominated by specialty drugs, many of which carry a six-figure annual per-patient cost. These drugs have become a driving force behind pharmaceutical expenditure for employer groups and present a challenge for

How employers and TPAs can ease the rising cost of specialty drugs with medical rebates Read More »

AlignRx President & CEO Kevin Kobielski Recognized in 2023 BenefitsPRO Luminaries Awards

BenefitsPRO, the No.1 provider of news, analysis and trends for benefits professionals, has announced its 2023 Luminaries Awards recognizing excellence in the benefits industry. Kevin Kobielski, president & CEO of AlignRx was recognized in the Leadership category.  One of only nine individuals awarded in this category this year, Kevin is featured in the October 2023 issue

AlignRx President & CEO Kevin Kobielski Recognized in 2023 BenefitsPRO Luminaries Awards Read More »

AlignRx Consulting Recognized on the 2023 Inc. 5000 List of Fastest Growing Companies

Inc. revealed today that AlignRx Consulting ranks No. 898 on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy’s most dynamic segment — its independent, entrepreneurial businesses.  AlignRx partners with benefit consultants, employer groups, TPAs

AlignRx Consulting Recognized on the 2023 Inc. 5000 List of Fastest Growing Companies Read More »

A Shake Up in the U.S. Insulin Market: Major Manufacturers Lower Insulin Costs

A new trend in insulin pricing? Here’s what you need to know. Insulin pricing has been a topic of concern and debate in recent years, as prices have skyrocketed, making it difficult for many patients with diabetes to afford the medication they need. However, the following recent announcements from major pharmaceutical manufacturers—who make up about

A Shake Up in the U.S. Insulin Market: Major Manufacturers Lower Insulin Costs Read More »